Enliven Therapeutics (ELVN) financial statements
Net income was -$104M.
Free cash flow was -$70M.
The diluted share count rose 7967% over the period (dilution).
Income statement
Fiscal years, from Enliven Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Research and development | $19M | $32M | $38M | $31M | $65M | $81M | $86M |
| Selling, general and admin | $5M | $10M | $13M | $8M | $19M | $24M | $34M |
| Operating income | -$24M | -$42M | -$51M | -$39M | -$84M | -$105M | -$120M |
| Pre-tax income | — | — | -$51M | $2M | — | — | — |
| Income tax | — | — | — | $88,000 | $0 | $232,000 | $0 |
| Net income | -$23M | -$41M | -$51M | -$38M | -$72M | -$89M | -$104M |
| EPS (diluted) | -$33.40 | -$3.53 | -$2.37 | -$12.05 | -$2.01 | -$1.89 | -$1.83 |
| Diluted shares | 1M | 14M | 22M | 3M | 36M | 47M | 57M |
Balance sheet
Fiscal years, from Enliven Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $29M | $88M | $90M | $88M | $253M | $313M | $463M |
| Total current assets | $31M | $90M | $93M | $78M | $266M | $318M | $475M |
| Property, plant and equipment | $442,000 | $349,000 | $250,000 | $890,000 | $742,000 | $458,000 | $34,000 |
| Total assets | $33M | $91M | $94M | $83M | $272M | $326M | $476M |
| Total current liabilities | $4M | $6M | $7M | $10M | $26M | $16M | $17M |
| Total liabilities | $4M | $6M | $8M | $10M | $26M | $16M | $17M |
| Shareholders' equity | -$49M | $84M | -$43M | -$77M | $246M | $310M | $460M |
| Net debt | -$5M | -$48M | -$48M | -$88M | -$100M | -$124M | -$99M |
Cash flow
Fiscal years, from Enliven Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$22M | -$37M | -$47M | -$32M | -$61M | -$73M | -$70M |
| Capital spending | $140,000 | $18,000 | $12,000 | $612,000 | $149,000 | $44,000 | $158,000 |
| Free cash flow | -$22M | -$37M | -$47M | -$33M | -$61M | -$73M | -$70M |
| Stock-based compensation | $899,000 | $2M | $4M | $3M | $13M | $20M | $34M |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for ELVN.
Open ELVN in InvestinglyQuestions
How much free cash flow does Enliven Therapeutics generate?
-$70M in fiscal 2025 (operating cash flow minus capital spending).
From Enliven Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.